Secondary hyperparathyroidism is a common complication of chronic kidney disease characterized by excessive secretion of parathyroid hormone from the parathyroid glands. Cinacalcet is a calcimimetic medication that reduces parathormone levels by increasing the sensitivity of the calcium-sensing receptors on the parathyroid glands. This review aims to summarize the existing literature on the use of cinacalcet in patients with secondary hyperparathyroidism.